In a child with nephrotic‑range proteinuria and severe hypoalbuminemia, is albumin infusion indicated for managing refractory edema?

Albumin Therapy for Refractory Edema in Pediatric Nephrotic Syndrome

Albumin infusion should be reserved for children with nephrotic syndrome who have clinical indicators of hypovolemia (oliguria, acute kidney injury, prolonged capillary refill time, tachycardia, hypotension, abdominal discomfort) or failure to thrive—not based on serum albumin levels alone. 1

Clinical Decision Framework

When to Use Albumin

Base the decision on clinical indicators of intravascular volume depletion, not laboratory values: 1

• Signs of hypovolemia requiring albumin: 1

  • Oliguria or acute kidney injury
  • Prolonged capillary refill time (>2 seconds)
  • Tachycardia
  • Hypotension
  • Abdominal discomfort
  • Failure to thrive despite adequate nutrition

• Do NOT use albumin based solely on: 1

  • Low serum albumin levels
  • Presence of edema alone without hypovolemia

Dosing Strategy

For severe disease with documented hypovolemia: 1

• Initiate daily albumin infusions at 1-4 g/kg
• Adjust frequency and dosage based on clinical response, not serum albumin levels

For stable patients: 1

• Reduce albumin dose as clinical status improves
• Space out infusions or discontinue entirely when hypovolemia resolves

Administration Technique

Sequential administration is superior to concurrent: 2

• Give furosemide 0.5-2 mg/kg IV immediately after (not during) albumin infusion 1
• This sequential method produces significantly greater weight loss compared to simultaneous administration 2
• Only administer furosemide if there is no marked hypovolemia or hyponatremia 1

Critical Safety Considerations

Vascular access: 1

• Avoid central venous lines (CVLs) whenever possible due to high thrombosis risk
• If CVL is necessary for repeated albumin infusions, provide prophylactic anticoagulation for the entire duration the line is in place
• Avoid peripherally inserted catheters and unnecessary venipunctures to preserve vessels for future dialysis access

Volume status assessment is paramount: 3

• Fractional excretion of sodium (FeNa) <0.2% identifies true volume contraction
• Patients with FeNa ≥0.2% have volume expansion and should receive diuretics alone, not albumin
• Volume-expanded patients treated with albumin risk precipitating fluid overload and pulmonary edema 1

Alternative Approach for Volume-Expanded Patients

Many children with severe edema have volume expansion, not contraction: 3

• These patients respond safely and effectively to diuretics alone (IV furosemide + oral spironolactone)
• No difference in hospital stay or weight loss compared to albumin-treated patients 3
• Avoids unnecessary albumin exposure and associated risks

Evidence Quality and Nuances

The 2021 ERKNET-ESPN consensus recommendations in Nature Reviews Nephrology provide the highest quality guidance specifically for congenital nephrotic syndrome, emphasizing clinical indicators over laboratory values 1. A 2019 Cochrane review found insufficient evidence to support routine albumin use, identifying only one small study with inconsistent results 4. However, a 2009 randomized crossover trial demonstrated that albumin plus furosemide produces significantly greater diuresis and natriuresis than furosemide alone in children with refractory edema 5. The 2025 study confirming superiority of sequential over concurrent administration provides practical guidance on optimal administration technique 2.

Common pitfall: Administering albumin based on low serum albumin levels rather than clinical hypovolemia leads to unnecessary treatment, increased thrombosis risk, and potential circulatory overload 1.

Quality of life consideration: Regular albumin infusions significantly impact school attendance and daily functioning, so the decision to initiate chronic therapy should weigh these factors 1.